SOPHiA GENETICS (NASDAQ:SOPH) Raised to “Hold” at Wall Street Zen

SOPHiA GENETICS (NASDAQ:SOPH) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.00.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $5.00 on Friday. The company has a market cap of $337.90 million, a PE ratio of -11.36 and a beta of 1.10. The stock’s 50 day simple moving average is $3.89 and its 200-day simple moving average is $3.42. SOPHiA GENETICS has a 1-year low of $2.58 and a 1-year high of $5.30. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.39 and a quick ratio of 3.21.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, August 5th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.58. The business had revenue of $18.32 million for the quarter, compared to the consensus estimate of $17.49 million. SOPHiA GENETICS had a negative return on equity of 30.69% and a negative net margin of 40.99%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SOPH. Ridgewood Investments LLC raised its position in SOPHiA GENETICS by 1,930.5% in the first quarter. Ridgewood Investments LLC now owns 40,610 shares of the company’s stock valued at $135,000 after purchasing an additional 38,610 shares during the period. Federated Hermes Inc. raised its position in SOPHiA GENETICS by 89.0% in the first quarter. Federated Hermes Inc. now owns 189,000 shares of the company’s stock valued at $627,000 after purchasing an additional 89,000 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares during the period. Silverberg Bernstein Capital Management LLC raised its position in SOPHiA GENETICS by 31.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock valued at $142,000 after purchasing an additional 11,040 shares during the period. Finally, Rathbones Group PLC purchased a new stake in SOPHiA GENETICS in the second quarter valued at $504,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.